Skip to content

Effects of Intralymphatic Allergen Immunotherapy in treatment of allergic rhinitis

Evaluation of the Effectiveness of Intralymphatic Allergen Immunotherapy in patients with Allergic Rhinitis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20161206031256N2
Enrollment
15
Registered
2018-03-02
Start date
2017-04-03
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis. Allergic rhinitis due to pollen

Interventions

3 intralymphatic inguinal injections under the guide of sonography( 1000 SQ-U Salsola-pollen extract within 4 weeks interval)..

Sponsors

Vice chancellor for research, Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with Seasonal or Perennial Allergic Rhinitis Aggravated symptoms from mid Summer till mid Autumn for at least two years Age :15-65 years Positive Skin Prick Test response to Salsola Kali Symptoms remain troublesome despite treatment The ability to comply with study procedures

Exclusion criteria

Exclusion criteria: Past history of Autoimmune Diseases Ongoing Systemic Immunosuppressive treatment. The presence of Pregnancy The presence of Immunodeficiency The presence of Allergic Asthma The presence of Heart Diseases Ongoing Beta Blocker or ACE inhibitors drug usage The presence of Malignancy The presence of any chronic diseases Current symptoms of Upper Respiratory Tract Infection History of life-threatening Anaphylaxis or Angioedema

Design outcomes

Primary

MeasureTime frame
Clinical Symptoms, Drug Usage, Skin Prick Test, Specific IgE. Timepoint: Befor The Trial. Method of measurement: Sign And Symptoms, Antiasthmatic Drugs Usage, Skin Prick Test, Peakflowmetry and Specific IgE.

Secondary

MeasureTime frame
Clinical symptoms, drug usage, specific IgE. Timepoint: One month after end of treatment. Method of measurement: Physical examination and peakflowmetry.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNasrin Sadat Motevalli Haghi

Mashhad Unevesity of Medical Science

dr.haghi@yahoo.com+98 51 3801 2829

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026